JennyJingyiFengMDMSc

Neurology • New Orleans, LA

Neuroimmunology/Multiple Sclerosis

Neuroimmunologist at Ochsner Health

Join to view full profile

Dr. Feng is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Feng's full profile

Already have an account?

Office
Ochsner Health
New Orleans, LA 70121
Is this information wrong?

Education & Training

Cleveland Clinic FoundationFellowship, Neuroimmunology & Multiple Sclerosis, 2018 - 2020
Cleveland Clinic FoundationResidency, Neurology, 2014 - 2018
University of Louisville School of MedicineClass of 2014
Washington University in St. LouisBA, Biology - Neuroscience

Certifications & Licensure

KY State Medical License 2020 - 2025
OH State Medical License 2014 - 2025
MS State Medical License 2021 - 2024
LA State Medical License 2021 - 2024
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

Best Teaching Award Ochsner Health Department of Neurology, 2023

Clinical Trials

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis Start of enrollment: 2021 Dec 16
Recruiting
Phase 3
Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis Start of enrollment: 2020 Nov 06
Active, not recruiting
Phase 1
Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls. Start of enrollment: 2022 Jan 25
Recruiting
Phase 4

Publications & Presentations

PubMed

Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption.
Barry A Singer, Jenny Feng, Horacio Chiong-Rivero> ;Journal of Neurology. 2024 Apr 14
Clinical observation during alemtuzumab administration.
Chris Allen, Jenny Feng, Mark Willis, Marisa P. McGinley, Daniel Ontaneda, Emma C. Tallantyre, Nikos Evangelou> ;Multiple Sclerosis and Related Disorders. 2020 Jan 1
10 citations
Serum neurofilament light chain concentration in a phase 1/2 trial of autologous mesenchymal stem cell transplantation:
Laura E. Baldassari, Sarah M. Planchon, Robert A. Bermel, Kunio Nakamura, Elizabeth Fisher, Jenny Feng, Kenneth Earl Sakaie, Daniel Ontaneda, Jeffrey A. Cohen> ;Multiple Sclerosis Journal - Experimental, Translational and Clinical. 2019 Nov 5
2 citations
Pembrolizumab-Induced CNS Vasculitis: Neurologic Adverse Events Due to Checkpoint Inhibitors.
Jenny Feng, Lindsay Ross, Daniel Ontaneda> ;Neurology. Clinical Practice. 2019 Nov 5
18 citations
Newer Treatment Approaches in Pediatric-Onset Multiple Sclerosis.
Gabrielle Macaron, Jenny Feng, Manikum Moodley, Mary Rensel> ;Current Treatment Options in Neurology. 2019 Sep 27
12 citations
Tuberculosis screening in multiple sclerosis: effect of disease-modifying therapies and lymphopenia on the prevalence of indeterminate TB screening results in the clin...
Laura E. Baldassari, Jenny Feng, Gabrielle Macaron, Sarah M. Planchon, Ebtesam Alshehri, Brandon P Moss, Daniel Ontaneda, Mary A. Willis> ;Multiple Sclerosis Journal - Experimental, Translational and Clinical. 2019 Sep 11
8 citations
Exploratory MRI measures after intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis:
Jenny Feng, Erik Offerman, Jian Lin, Elizabeth Fisher, Sarah M. Planchon, Kenneth Earl Sakaie, Mark J. Lowe, Kunio Nakamura, Jeffrey A. Cohen, Daniel Ontaneda> ;Multiple Sclerosis Journal - Experimental, Translational and Clinical. 2019 Jun 14
Join now to see all

Press Mentions

#MSVirtual2020 – Pediatric MS Patients May Do Best on Intravenous DMTs, Study FindsSeptember 16th, 2020
ACTRIMS Forum: MS Research Updates on the Microbiome, Diet, Brain Networks, and New FrontiersMarch 6th, 2020
MS News That Caught My Eye Last Week: Remyelination Research in Animal Models, Depression and Neurological Function, Ofatumumab Approval Moves CloserMarch 2nd, 2020